Amicus Therapeutics is a biopharmaceutical company at the forefront of therapies for rare and orphan diseases. The Company has a robust pipeline of novel, first-in-class treatments in development for a broad range of human genetic diseases, with a focus on delivering new benefits to individuals with lysosomal storage diseases (LSDs).

Private Funding Events

DateOfferedSoldType
2013-12-03$15,000,000$15,000,000Equity
2013-12-03$15,000,000$15,000,000Equity, Option to Acquire
2012-07-30$18,582,360$18,582,360Equity
2010-11-05$31,284,583$31,284,583Equity
2007-05-25UnknownUnknownOther (Paper Filing)

Key Executives

  • John F Crowley
    Executive Officer, Director
  • Matthew R Patterson
    Executive Officer
  • David Lockhart
    Executive Officer
  • Pol F Boudes
    Executive Officer
  • Geoffrey P Gilmore
    Executive Officer
  • S Nicole Schaeffer
    Executive Officer
  • Bradley L Campbell
    Executive Officer
  • John R Kirk
    Executive Officer
  • Ken Valenzano
    Executive Officer
  • James Barrett
    Director
  • Sol J Barer
    Director
  • Alexander E Barkas
    Director
  • Donald J Hayden
    Director
  • Margaret G McGlynn
    Director
  • P Sherrill Neff
    Director
  • Michael G Raab
    Director
  • Glenn P Sblendorio
    Director
  • James N Topper
    Director
  • John F. Crowley
    Executive Officer, Director
  • David J. Lockhart
    Executive Officer
  • Pol F. Boudes
    Executive Officer
  • Bradley L. Campbell
    Executive Officer
  • William D. Baird, III
    Executive Officer
  • Donald J. Hayden, Jr.
    Director
  • Sol J. Barer
    Director
  • Margaret G. McGlynn
    Director
  • Michael G. Raab
    Director
  • Glenn Sblendorio
    Director
  • James N. Topper
    Director
  • Ted W. Love
    Director
  • Robert Essner
    Director
  • Daphne Quimi
    Executive Officer
  • John R. Kirk
    Executive Officer
  • Enrique Dilone
    Executive Officer
  • Kenneth W. Peist
    Executive Officer
  • Robert Winkler
    Executive Officer
  • Joan C. Winterbottom
    Executive Officer
  • Jayne Gerskowitz
    Executive Officer
  • Jeffrey P. Castelli
    Executive Officer
  • Jeffrey Castelli
    Executive Officer